BRPI0715396A2 - Vacinas de matriz proteíca e processos de produção e de administração de tais vacinas - Google Patents

Vacinas de matriz proteíca e processos de produção e de administração de tais vacinas

Info

Publication number
BRPI0715396A2
BRPI0715396A2 BRPI0715396-1A2A BRPI0715396A BRPI0715396A2 BR PI0715396 A2 BRPI0715396 A2 BR PI0715396A2 BR PI0715396 A BRPI0715396 A BR PI0715396A BR PI0715396 A2 BRPI0715396 A2 BR PI0715396A2
Authority
BR
Brazil
Prior art keywords
vaccines
production
protein matrix
administration processes
administration
Prior art date
Application number
BRPI0715396-1A2A
Other languages
English (en)
Inventor
John J Mekalanos
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BRPI0715396A2 publication Critical patent/BRPI0715396A2/pt
Publication of BRPI0715396B1 publication Critical patent/BRPI0715396B1/pt
Publication of BRPI0715396B8 publication Critical patent/BRPI0715396B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0283—Shigella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
BRPI0715396A 2006-08-07 2007-08-07 método de produção de uma composição para vacina BRPI0715396B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83594406P 2006-08-07 2006-08-07
US60/835,944 2006-08-07
US93376407P 2007-06-08 2007-06-08
US60/933,764 2007-06-08
PCT/US2007/017528 WO2008021076A2 (en) 2006-08-07 2007-08-07 Protein matrix vaccines and methods of making and administering such vaccines

Publications (3)

Publication Number Publication Date
BRPI0715396A2 true BRPI0715396A2 (pt) 2013-11-26
BRPI0715396B1 BRPI0715396B1 (pt) 2019-02-19
BRPI0715396B8 BRPI0715396B8 (pt) 2021-05-25

Family

ID=39082551

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0715396A BRPI0715396B8 (pt) 2006-08-07 2007-08-07 método de produção de uma composição para vacina

Country Status (12)

Country Link
US (3) US8642042B2 (pt)
EP (2) EP3260134A1 (pt)
JP (2) JP5745221B2 (pt)
KR (1) KR101446238B1 (pt)
AU (1) AU2007284878B2 (pt)
BR (1) BRPI0715396B8 (pt)
CA (1) CA2660022C (pt)
DK (1) DK2056871T3 (pt)
ES (1) ES2658851T3 (pt)
MX (1) MX2009001412A (pt)
TW (1) TWI565713B (pt)
WO (1) WO2008021076A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008021076A2 (en) * 2006-08-07 2008-02-21 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines
US8524394B2 (en) * 2007-11-22 2013-09-03 Samsung Sdi Co., Ltd. Negative electrode and negative active material for rechargeable lithium battery, and rechargeable lithium battery including same
CA2730328C (en) 2008-09-03 2015-03-31 Board Of Trustees Of Michigan State University Immunogenic escherichia coli heat stable enterotoxin
US8647621B2 (en) 2009-07-27 2014-02-11 Fina Biosolutions, Llc Method of producing protein-carbohydrate vaccines reduced in free carbohydrate
EP2473188A4 (en) * 2009-09-09 2014-01-01 Matrivax Res & Dev Corp PROTEIN MATRIX VACCINES WITH IMPROVED IMMUNOGENICITY
US20110135689A1 (en) * 2009-11-30 2011-06-09 University Of Iowa Research Foundation Vaccine, therapeutic composition and methods for treating or inhibiting francisella tularenis
CA2836140C (en) 2009-12-17 2016-06-21 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
ES2743156T3 (es) 2010-04-23 2020-02-18 Serum Institute Of India Pvt Ltd Método simple para eliminación simultánea de múltiples impurezas a partir de sobrenadantes de cultivo a niveles ultrabajos
EP2566508B1 (en) * 2010-05-03 2015-07-22 Dcb-Usa Llc Polysaccharide conjugation with detoxified e. coli heat labile enterotoxin (lt) used as vaccine
CN103747798B (zh) * 2011-05-18 2018-10-26 马特里瓦克斯公司 包含聚阳离子的蛋白质基质疫苗组合物
EP3628329B1 (en) 2011-09-30 2022-08-10 Dana-Farber Cancer Institute, Inc. Therapeutic peptides comprising antibodies binding to mhc class 1 polypeptide related sequence a (mica)
EP2946010B1 (en) 2013-01-18 2018-08-29 London School of Hygiene and Tropical Medicine Glycosylation method
GB201301085D0 (en) * 2013-01-22 2013-03-06 London School Hygiene & Tropical Medicine Glycoconjugate Vaccine
WO2014144791A2 (en) 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Therapeutic peptides
WO2015073831A1 (en) * 2013-11-15 2015-05-21 Liquidia Technologies, Inc. Virtual conjugate particles
MX371454B (es) 2014-01-21 2020-01-29 Pfizer Polisacaridos capsulares de streptococcus pneumoniae y conjugados de los mismos.
US20170198054A1 (en) * 2014-05-21 2017-07-13 Dana-Farber Cancer Institute Methods for treating cancer with anti bip or anti mica antibodies
US9107906B1 (en) 2014-10-28 2015-08-18 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
WO2018009906A1 (en) * 2016-07-08 2018-01-11 President And Fellows Of Harvard College Whole cell-protein conjugates and methods of making the same
SG11201901394XA (en) 2016-09-02 2019-03-28 Sanofi Pasteur Inc Neisseria meningitidis vaccine
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
AU2018280272C1 (en) * 2017-06-10 2021-05-06 Inventprise, Inc. Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP2020536968A (ja) 2017-10-13 2020-12-17 ザ リサーチ ファウンデイション フォー ザ ステイト ユニバーシティー オブ ニューヨーク 共生疾患進行に対する包括的ワクチン設計
CA3084436A1 (en) 2017-12-06 2019-07-18 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CA3120922A1 (en) * 2018-12-12 2020-06-18 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
AU2019401535B2 (en) 2018-12-19 2023-12-14 Merck Sharp & Dohme Llc Compositions comprising Streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CN114129719A (zh) * 2021-12-03 2022-03-04 张公义 广谱疫苗的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4707543A (en) * 1985-09-17 1987-11-17 The United States Of America As Represented By The Secretary Of The Army Process for the preparation of detoxified polysaccharide-outer membrane protein complexes, and their use as antibacterial vaccines
US4761470A (en) * 1985-12-16 1988-08-02 Merck & Co., Inc. Immunogenic synthetic peptide capable of eliciting herpes simplex virus neutralizing antibody
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
CA2107106A1 (en) 1991-03-28 1992-09-29 Jo Klaveness Cross-linking agent
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
US5545669A (en) 1994-06-02 1996-08-13 Adams; Jerry L. Anti-inflammatory compounds
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CA2232410C (en) * 1995-09-18 2003-06-17 United States Army Medical Research Materiel Command (Usamrmc) Improved methods for the production of non-covalently complexed and multivalent proteosome sub-unit vaccines
US6821331B2 (en) * 2003-04-09 2004-11-23 Wisconsin Alumni Research Foundation Protein-polysaccharide hybrid hydrogels
EP1522585A1 (en) * 2003-10-09 2005-04-13 Plant Research International B.V. Chimeric carrier molecules for the production of mucosal vaccines
WO2008021076A2 (en) * 2006-08-07 2008-02-21 President And Fellows Of Harvard College Protein matrix vaccines and methods of making and administering such vaccines

Also Published As

Publication number Publication date
US8642042B2 (en) 2014-02-04
EP3260134A1 (en) 2017-12-27
JP2010500354A (ja) 2010-01-07
TW200823230A (en) 2008-06-01
KR101446238B1 (ko) 2014-10-01
US20140186399A1 (en) 2014-07-03
US20160136257A1 (en) 2016-05-19
EP2056871A2 (en) 2009-05-13
US9216223B2 (en) 2015-12-22
WO2008021076A3 (en) 2008-12-04
BRPI0715396B8 (pt) 2021-05-25
EP2056871A4 (en) 2010-04-14
US9533032B2 (en) 2017-01-03
DK2056871T3 (en) 2018-02-26
JP5745221B2 (ja) 2015-07-08
AU2007284878B2 (en) 2013-01-17
TWI565713B (zh) 2017-01-11
AU2007284878A1 (en) 2008-02-21
EP2056871B1 (en) 2017-11-15
CA2660022C (en) 2014-11-04
US20080095803A1 (en) 2008-04-24
WO2008021076A2 (en) 2008-02-21
KR20090066272A (ko) 2009-06-23
CA2660022A1 (en) 2008-02-21
BRPI0715396B1 (pt) 2019-02-19
JP2014058530A (ja) 2014-04-03
MX2009001412A (es) 2009-04-24
ES2658851T3 (es) 2018-03-12

Similar Documents

Publication Publication Date Title
BRPI0715396A2 (pt) Vacinas de matriz proteíca e processos de produção e de administração de tais vacinas
DK1976559T6 (da) Influenzavacciner indeholdende hæmagglutinin og matrixproteiner
DK1973429T3 (da) Proteinhydrolysater og fremgangsmåde til fremstilling
DK2104737T3 (da) Funktioner og formål for let-7 mikro-RNAer
DK3136030T3 (da) Fremgangsmåde til lyofilisering
DK2273975T3 (da) Farmaceutiske opløsninger, fremgangsmåde til fremstilling og terapeutiske anvendelser
BRPI0717317A2 (pt) Modularoes da proteína cinase triazalopiridazina
BRPI1014864A2 (pt) "implante de processos espinhosos e métodos associados"
DK2001903T3 (da) Langtidsvirkende polypeptider og fremgangsmåder til fremstilling og administration deraf
ATE552336T1 (de) Herstellung biologisch aktiver proteine
ATE522624T1 (de) Identifizierung von krankheitserregern
SMAP200700023A (it) Dispositivi e metodi per iniezioni di medicinali
IL193473A0 (en) Amide derivatives and their application for the treatment of g protein related diseases
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
BRPI0716472A2 (pt) Sistema de tratamento ultassônico e método de usar o sistema
DE06722936T8 (de) Isomerisation pharmazeutischer zwischenprodukte
DK2029799T3 (da) Termostabile proteiner og fremgangsmåder til fremstilling og anvendelse heraf
IL193283A0 (en) Drug delivery system and method of method of manufacturing thereof
DK2352509T3 (da) Hla-g-proteiner og farmaceutiske anvendelser deraf
BRPI0920246A2 (pt) método de preparação de alfa-beta peptídios biologicamente ativos.
DE602008001585D1 (de) Physikalischer Sensor und Herstellungsverfahren
DK2274619T3 (da) Slimhindereceptor og anvendelser deraf
BRPI0814363A2 (pt) Produtos fármacos de interferon de liberação controlada e tratamento de infecção por hcv usando os mesmos
ATE497504T1 (de) Aminoderivate von b-homoandrostanen und b- heteroandrostanen
BRPI0810057A2 (pt) Composição farmacêutica contendo floroglucinol e paracetamol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 19/02/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/08/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF